Copertina

Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Nikolaj Torp, Mads Israelsen, Stine Johansen, Aleksander Krag
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
di: Stine Johansen, et al.
Pubblicazione: (2026)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
di: Yewan Park, et al.
Pubblicazione: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Editorial: MetALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan?
di: Hannes Hagström, et al.
Pubblicazione: (2025)

M et ALD : Diagnosis and Prognosis With Non‐Invasive Tests
di: Nikolaj Torp, et al.
Pubblicazione: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
di: Qiang Hu, et al.
Pubblicazione: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD
di: Zhe‐Kun Xiong, et al.
Pubblicazione: (2025)

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
di: Muhammad Abubakr, et al.
Pubblicazione: (2025)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
di: Yewan Park, et al.
Pubblicazione: (2024)

Editorial: M et ALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan? Authors' Reply
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
di: Shuaibing Ying, et al.
Pubblicazione: (2026)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply
di: Ryan M. Mathias, et al.
Pubblicazione: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
di: Daniel Q. Huang, et al.
Pubblicazione: (2026)

Editorial: UDCA Dosing in PBC—Between Guideline Adherence and Clinical Reality: Authors' Reply
di: Ellen Werner, et al.
Pubblicazione: (2026)

Editorial: TIPS in the Era of Aging and Metabolic Comorbidity—Rethinking Risks and Rewards. Authors Reply
di: Michelle Spaan, et al.
Pubblicazione: (2026)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
di: Ramin Ebrahimi, et al.
Pubblicazione: (2025)

Editorial: Clinical Impact of Lipid Profile Change After DAA Treatment in CHC Patients—Authors' Reply
di: Zahra Sarrafan‐Chaharsoughi, et al.
Pubblicazione: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
di: Máté Szilcz, et al.
Pubblicazione: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
di: Jeongkuk Seo, et al.
Pubblicazione: (2024)

Editorial: ‘Risk‐Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome’. Authors' Reply
di: Hermann Brenner, et al.
Pubblicazione: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
di: Raj Vuppalanchi, et al.
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
di: Fai Fai Ho, et al.
Pubblicazione: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
di: Parul Tandon, et al.
Pubblicazione: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
di: Bharati Kochar, et al.
Pubblicazione: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
di: Jeffrey D McCurdy, et al.
Pubblicazione: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
di: David Mehdi Asgher Niazi, et al.
Pubblicazione: (2026)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC—Authors' Reply
di: Subin Heo, et al.
Pubblicazione: (2025)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
di: Jonggi Choi
Pubblicazione: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
di: Jessica D. Lee, et al.
Pubblicazione: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2026)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
di: Teresa Seum, et al.
Pubblicazione: (2025)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
di: Chia‐Chih Kuo, et al.
Pubblicazione: (2025)

Letter: Enhancing HCC Surveillance: GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety—Authors' Reply
di: Gamal Shiha, et al.
Pubblicazione: (2025)

Editorial: The Devil Is in the Detail—Interpreting the Findings of Network Meta‐Analyses. Authors' Reply
di: Mohammad Shehab, et al.
Pubblicazione: (2025)